OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Biological Therapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	120
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	63
Biosimilars and access to biologic therapy in immune-mediated diseases	56
Antibody drug conjugates for glioblastoma: current progress towards clinical use	55
A comprehensive overview on the anti-inflammatory, antitumor, and ferroptosis functions of bromelain: an emerging cysteine protease	53
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions	53
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	50
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	42
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol	38
Aflibercept biosimilars – so near, yet so far	38
The endosomal-lysosomal system in ADC design and cancer therapy	36
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	33
Development and Clinical Translation Considerations for the Next Wave of Gene Modified Hematopoietic Stem and Progenitor Cells Therapies	30
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences	27
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	27
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	27
Correction	25
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	24
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	24
Signaling new therapeutic opportunities: cytokines in prostate cancer	23
Long-acting delivery and therapies for neovascular age-related macular degeneration	23
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	23
Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors	22
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	21
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies	20

Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	20
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	20
Correction	20
Strategies for extending the half-life of biotherapeutics: successes and complications	20
Unmet needs in cervical cancer – can biological therapies plug the gap?	20
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis	19
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	19
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	18
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	18
An evaluation of guselkumab for the treatment of ulcerative colitis	18
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	18
Correction	18
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	18
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	18
The nail in psoriatic arthritis: new insights into prognosis and treatment	17
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	17
Dynamics of biological markets with multiple biosimilar competitors in the United States	17
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	17
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	16
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	16
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	16
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	16
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	16
Management of proctitis in ulcerative colitis and the place of biological therapies	16
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	15
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	15
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	15
Where do we stand with radioimmunotherapy for acute myeloid leukemia?	15
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	14
Recent advances in delivering RNA-based therapeutics to mitochondria	14
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	14
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	14
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	14
Biological agents targeting interleukin-13 for atopic dermatitis	13
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	13
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	13
Psoriatic arthritis improved on risankizumab: does the presence of psoriatic arthritis mean a drug approved for psoriatic arthritis has to be prescribed?	13
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	13
An evaluation of pozelimab for the treatment of CHAPLE disease	13
Efficacy of trastuzumab in HER-2-positive advanced extramammary Paget’s disease	13
Emerging peptide-based technology for biofilm control	13
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	13
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	13
Fecal microbiota transplantation: a review on current formulations inClostridioides difficileinfection and future outlooks	12
Belimumab patient profile in Spain: evolution during the last decade and future directions	12
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence	12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients	12
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	12
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	12
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	12

Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	12
Treating psoriasis in the elderly: biologics and small molecules	12
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	12
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	11
Tremelimumab for the treatment of hepatocellular carcinoma	11
Clinical management and innovation in fracture non-union	11
Correction	11
Biosimilars in osteoporosis treatment: focus on denosumab	11
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	11
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects	11
Non-traditional approaches for control of antibiotic resistance	11
Antibody therapeutics for epithelial ovarian cancer	11
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	10
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	10
Harmonizing PD-L1 testing in metastatic triple negative breast cancer	10
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics	10
Prospects of cell chemotactic factors in bone and cartilage tissue engineering	10
Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms	10
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	10
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	10
X-linked myotubular myopathy: an untreated treatable disease	10
Epcoritamab in B-cell malignancies: current status and prospects	10
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	10
Prostate cancer immunotherapy	10
Biologics in rectal cancer	9
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	9
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	9
Hemophilia A gene therapy: current and next-generation approaches	9
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	9
Sargramostim in acute radiation syndrome	9
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	9
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	9
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	9
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	9
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	9
Rilonacept for the treatment of recurrent pericarditis	9
Ravulizumab for the treatment of myasthenia gravis	9
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	9
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	8
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	8
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	8
Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus	8
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	8
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	8
The future of interleukin gene therapy in head and neck cancers	8
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	8
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey	8
The future of cellular therapy for the treatment of renal cell carcinoma	8
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	8
CAR T cells for solid tumors – developments to watch in 2023	8
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	8
Belantamab mafodotin in multiple myeloma	8
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	8